Results 31 to 40 of about 20,750 (203)

Phase I/II trial of concurrent extracranial palliative radiation therapy with Dabrafenib and Trametinib in metastatic BRAF V600E/K mutation-positive cutaneous Melanoma

Clinical and Translational Radiation Oncology, 2021
Background: Concurrent treatment with BRAF inhibitors and palliative radiation therapy (RT) could be associated with increased toxicity, especially skin toxicity.
Wei Wang, Jessica Louise Smith, Matteo Salvatore Carlino, Bryan Burmeister, Mark Blayne Pinkham, Gerald Blaise Fogarty, David Robert Harry Christie, Vanessa Estall, Mark Shackleton, Arthur Clements, Rory Wolfe, Le Thi Phuong Thao, Elizabeth Jane Paton, Victoria Steel, Narelle Catherine Williams   +14 more
doaj   +1 more source

MicroRNAs in melanoma development and resistance to target therapy [PDF]

, 2017
microRNAs constitute a complex class of pleiotropic post-transcriptional regulators of gene expression involved in the control of several physiologic and pathologic processes.
Ascierto, Paolo Antonio, Ciliberto, Gennaro, Costantini, Susan, Croce, Carlo M, Fattore, Luigi, Malpicci, Debora, Mancini, Rita, Ruggiero, Ciro Francesco   +7 more
core   +1 more source

Dabrafenib, an inhibitor of RIP3 kinase-dependent necroptosis, reduces ischemic brain injury

Neural Regeneration Research, 2018
Ischemic brain injury triggers neuronal cell death by apoptosis via caspase activation and by necroptosis through activation of the receptor-interacting protein kinases (RIPK) associated with the tumor necrosis factor-alpha (TNF-α)/death receptor. Recent
Shelly A Cruz, Zhaohong Qin, Alexandre F. R. Stewart, Hsiao-Huei Chen   +3 more
doaj   +1 more source

Safety and rapid response of dabrafenib and trametinib therapy during hyperbilirubinemia in metastatic melanoma

Frontiers in Oncology, 2023
This case report describes the occurrence of hyperbilirubinemia as a complication of metastatic melanoma. A 72-year-old male patient was diagnosed with BRAF V600E-mutated melanoma with metastases in the liver, lymph nodes, lungs, pancreas, and stomach ...
Walid Shalata, Rachel Steckbeck, Ilya Polishchuk, Ahron Yehonatan Cohen, Keren Rouvinov, Margarita Tokar, Ashraf Abu Jama, Omar Abu Saleh, Omar Abu Saleh, Kim Sheva, Alexander Yakobson   +10 more
doaj   +1 more source

A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours [PDF]

, 2016
Purpose: We performed a multi-centre phase I study to assess the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of the orally available small molecule mitogen-activated protein kinase kinase (MEK) 1/2 inhibitor, WX-554, and to determine the ...
Allen, Rodger, Anthoney, Alan, Banerji, Udai, Bevan, Paul, Boddy, Alan V., Buerkle, Markus, Coyle, Vicky, Cresti, Nicola, Dean, Emma, Drew, Yvette, Evans, T.R. Jefferey, Greystoke, Alastair, Griffin, Melanie J., Jamieson, David, Mala, Carola, Merriman, Mark, Plummer, Ruth, Ranson, Malcolm, Rodgers, Lisa, Sludden, Julieann, Swales, Karen, Wilson, Richard H.   +21 more
core   +2 more sources

A case of recurrent bilateral uveitis independently associated with dabrafenib and pembrolizumab therapy

American Journal of Ophthalmology Case Reports, 2016
Purpose: To report the case of an adult female who presented on different occasions with recurrent uveitis provoked by initiating therapy of two recently approved agents, dabrafenib and pembrolizumab, for treatment of metastatic melanoma. Observations: A
Stanford C. Taylor, Frank Hrisomalos, Gerald P. Linette, P. Kumar Rao   +3 more
doaj   +1 more source

An advanced pulmonary sarcomatoid carcinoma patient harboring a BRAFV600E mutation responds to dabrafenib and trametinib: a case report and literature review

Frontiers in Oncology, 2023
BackgroundThe pulmonary sarcomatoid carcinoma (PSC) is a rare and aggressive subtype of NSCLC with rapid progression and poor prognosis, and is resistant to conventional chemotherapy.
Ruoxin Fang, Jun Gong, Zhengkai Liao
doaj   +1 more source

Resistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma. [PDF]

, 2017
The advent of genomics has led to the identification of specific "driver" mutations in oncogenic kinases, and the development of targeted small molecule inhibitors to block their tumor-driving functions.
Bivona, Trever G, Neel, Dana S
core   +1 more source

Dabrafenib protects from cisplatin-induced hearing loss in a clinically relevant mouse model

JCI Insight, 2023
The widely used chemotherapy cisplatin causes permanent hearing loss in 40%–60% of patients with cancer. One drug, sodium thiosulfate, is approved by the FDA for use in pediatric patients with localized solid tumors for preventing cisplatin-induced ...
Matthew A. Ingersoll, Richard D. Lutze, Chithra K. Pushpan, Regina G. Kelmann, Huizhan Liu, Mark T. May, William J. Hunter, David Z.Z. He, Tal Teitz   +8 more
doaj   +1 more source

Characterization of dabrafenib-induced drug insensitivity via cellular barcoding and collateral sensitivity to second-line therapeutics

Scientific Reports
Drug insensitivity is arguably one of the biggest challenges in cancer therapeutics. Although effective therapeutic solutions in cancer are limited due to the emergence of drug insensitivity, exploiting evolutionary understanding in this context can ...
Rana Can Baygin, Kubra Celikbas Yilmaz, Ahmet Acar   +2 more
doaj   +1 more source